S6K Cellular Phosphorylation Assay (intracellular kinase activity assay) for compound screening and profiling in intact cells
p70-S6K is a serine/threonine kinase downstream of the PI3K/AKT/mTOR pathway and belongs to the family of ribosomal S6 kinases (RSKs). It phosphorylates several residues of the 40S ribosomal protein S6 and of several other translational-regulatory factors, which results in increased protein synthesis and cell proliferation. The kinase is activated via direct phosphorylation by the protein complex mTORC1. In breast cancer cell lines and patient tumor samples overexpression of p70-S6K was found and correlated with poor prognosis.
RPS6KB1
S6K, STK14A, P70S6K
Karpa-299
Endogenous
In the human T cell lymphoma cell line Karpas-299 the serine/threonine kinase p70-S6K is constitutively activated via its direct upstream kinase mTORC1. Inhibition of the mTORC1 protein complex with a specific inhibitor like Everolimus results in inactivation of S6K causing a decrease of phospho-levels of the S6K substrate 40S ribosomal protein S6 (see Fig. 1). Therefore, the cellular S6K phosphorylation assay can be used for the characterization of inhibitors of S6K as well as inhibitors of mTORC1. In the assay levels of phospho-Ser235/236 of S6 are quantified by Sandwich-ELISA technique.
Substrate phosphorylation as a readout of intracellular kinase activity via ELISA
Freiburg, Germany
More information can be found on our website Cellular Phosphorylation Assay Services.
Reference compound IC50 for S6K
Everolimus specifically blocks the activation of p70-S6 kinase by inhibiting the mTORC1 protein, which is a direct upstream kinase complex of p70-S6K. Reduced activation of p70-S6 kinase subsequently results in reduction of phosphorylation of the S6 protein at Ser235/236. Everolimus shows highly reproducible IC50 values in the cellular p70-S6K assay. The graph shows the result of a representative experiment.